FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s WegovyNovo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which Share XFDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovyhttps://pharmaphorum.com/news/fda-ends-obesity-drug-drought/
Gilead pushes on with NASH partnership with Novo NordiskGilead is one of many pharmas chasing mega-bucks promised by the fatty liver disease known as NASH – Share XGilead pushes on with NASH partnership with Novo Nordiskhttps://pharmaphorum.com/news/gilead-pushes-on-with-nash-partnership-with-novo-nordisk/
Novo Nordisk’s semaglutide effective against obesity in new trialNovo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, Share XNovo Nordisk’s semaglutide effective against obesity in new trialhttps://pharmaphorum.com/news/novo-nordisks-semaglutide-effective-obesity-new-trial/
Gilead and Novo plot next steps after trial data from NASH comboGilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked Share XGilead and Novo plot next steps after trial data from NASH combohttps://pharmaphorum.com/news/gilead-and-novo-plot-next-steps-after-encouraging-data-from-nash-combo/
Towards a new understanding of cardiovascular risk in diabetesA new post-hoc analysis from Novo Nordisk of their SUSTAIN 6 and PIONEER 6 studies into semaglutide is Share XTowards a new understanding of cardiovascular risk in diabeteshttps://pharmaphorum.com/r-d/views-analysis-r-d/towards-a-new-understanding-of-cardiovascular-risk-in-diabetes/
Novo’s new oral GLP-1 Rybelsus still has obstacles to overcomeThe FDA approval last Friday of Novo Nordisk’s Rybelsus as the first orally-active GLP-1 agonist is only the Share XNovo’s new oral GLP-1 Rybelsus still has obstacles to overcomehttps://pharmaphorum.com/news/novos-new-oral-glp-1-still-has-obstacles-to-overcome/
Gilead and Novo Nordisk collaborate for NASH trialGilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) Share XGilead and Novo Nordisk collaborate for NASH trialhttps://pharmaphorum.com/news/gilead-and-novo-nordisk-collaborate-for-nash-trial/
Novo’s oral semaglutide on target in phase 3 trialNovo Nordisk continues to build a case for its oral semaglutide GLP-1 class diabetes drug, with latest results Share XNovo’s oral semaglutide on target in phase 3 trialhttps://pharmaphorum.com/news/novos-oral-semaglutide-target-phase-3-trial/
Novo’s diabetes pill beats injections in head-to-head trialsNovo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight Share XNovo’s diabetes pill beats injections in head-to-head trialshttps://pharmaphorum.com/news/novo-nordisks-success-with-oral-diabetes-drug/
